Through SRB assays, colony survival assays, and spheroid formation, we found that when combining them with EGFR-TKI, they displayed an enhanced inhibition of tumor cell proliferation when compared with single drugs in the resistant cells. The gene discussed is EGFR; the disease is neoplasm.